A novel animal model for motion sickness and its first application in rodents

Physiology and Behavior

Volumn 92, Issue 4, 2007, Pages 702-707

  Yu, Xu Hong ^a   Cai, Guo Jun ^a   Liu, Ai Jun ^a   Chu, Zheng Xu ^a   Su, Ding Feng ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

Author keywords

Animal model; Kaolin; Mice; Modafinil; Motion sickness; Rat; Scopolamine

Indexed keywords

KAOLIN; MODAFINIL; SCOPOLAMINE;

ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; FOOD INTAKE; MOTION SICKNESS; NONHUMAN; PRIORITY JOURNAL; RAT; STATISTICAL ANALYSIS;

EID: 35548933222     PISSN: 00319384     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.physbeh.2007.05.067     Document Type: Article

References (25)

1. Money K.E. Motion sickness. Physiol Rev 50 (1970) 1-39
2. Muth E.R. Motion and space sickness: intestinal and autonomic correlates. Auton Neurosci 129 (2006) 58-66
3. Reason J.T. Motion sickness adaptation: a neural mismatch model. J Royal Soc Med 71 (1978) 819-829
4. Borison H.L. Area postrema: chemoreceptor circumventricular organ of the medulla oblongata. Prog Neurobiol 32 (1989) 351-390
5. McCaffrey R.J. Appropriateness of kaolin consumption as an index of motion sickness in the rat. Physiol Behav 35 (1985) 151-156
6. Mitchell D., Krusemark M.L., and Hafner D. Pica: a species relevant behavioural assay of motion sickness in the rat. Physiol Behav 18 (1977) 125-130
7. Receptor antagonist CP-99,994. Neuropharmacology 34 (1995) 1697-1699
8. Rudd J.A., Ngan M.P., and Wai M.K. Inhibition of emesis by tachykinin NK1 receptor antagonists in Suncus murinus (house musk shrew). Eur J Pharmacol 366 (1999) 243-252
9. Smith J.E., Friedman M.I., and Andrews P.L.R. Conditioned food aversion in Suncus murinus (house musk shrew)-a new model for the study of nausea in a species with an emetic reflex. Physiol Behav 73 (2001) 593-598
10. Santucci D., Corazzi G., Francia N., Antonelli A., Aloe L., and Alleva E. Neurobehavioral effects of hypergravity conditions in adult mouse. NeuroReport 11 (2000) 3353-3356
11. Liu Y.L., Malik N., Sanger G.J., Friedman M.I., and Andrews P.L. Pica-a model of nausea? Species differences in response to cisplatin. Physiol Behav 85 (2005) 271-277
12. Graybiel A., Miller E.F., and Homick J.L. Human vestibular function. In: Biomedical Results From Skylab (1977), NASA, Washington, DC 74-103
13. Holtmann S., Clarke A.H., Scherer H., and Hohn M. The anti-motion sickness mechanism of ginger: a comparative study with placebo and dimenhydrinate. Acta Otolaryngol 108 (1989) 168-174
14. Stott J.R.R., Barnes G.R., Wright R.J., and Ruddock C.J. The effect on motion sickness and oculomotor function of GR 38032F, a 5-HT3-receptor antagonist with anti-emetic properties. Br J Clin Pharmacol 27 (1989) 147-157
15. Stern R.M., Uijtdehaage S.H.J., Muth E.R., and Koch K.L. Effects of phenytoin on vection-induced motion sickness and gastric myoelectric activity. Aviat Space Environ Med 65 (1994) 518-521
16. Muth E.R., Jokerst M., Stern R.M., and Koch K.L. Effects of dimenhydrinate on gastric tachyarrhythmia and symptoms of vection-induced motion sickness. Aviat Space Environ Med 66 (1995) 1041-1045
17. Kohl R.L., and MacDonald S. New pharmacologic approaches to the prevention of space/motion sickness. J Clin Pharmacol 31 (1991) 934-946
18. Uijtdehaage S.H.J., Stern R.M., and Koch K.L. Effects of scopolamine on autonomic profiles underlying motion sickness susceptibility. Aviat Space Environ Med 64 (1993) 1-8
19. Pingree B.J.W., and Pethybridge R.J. A comparison of the efficacy of cinnarizine with scopolamine in the treatment of motion sickness. Aviat Space Environ Med 65 (1994) 597-605
20. Schmid R., Schick T., Steffen R., Tschopp A., and Torgeir W. Comparison of seven commonly used agents for prophylaxis of seasickness. J Travel Med 1 (1994) 203-206
21. Bastuji H., and Jouvet M. Successful treatment of idiopathic hypersomnia and narcolepsy with modafinil. Prog Neuro-psychopharmacol Biol Psychiatry 12 (1988) 695-700
22. Madras B.K., Xie Z., Lin Z., Jassen A., Panas H., Lynch L., et al. Modafinil occupies dopamine and norepinephrine transporters in vivo and modulates the transporters and trace amine activity in vitro. J Pharmacol Exp Ther 319 (2006) 561-569
23. Banerjee D., Vitiello M.V., and Grunstein R.R. Pharmacotherapy for excessive daytime sleepiness. Sleep Med Rev 8 (2004) 339-354
24. Lin J.S., Hou Y., and Jouvet M. Potential brain neuronal targets for amphetamine-, methylphenidate-, and modafinil-induced wakefulness, evidenced by c-fos immunocytochemistry in the cat. Proc Natl Acad Sci U S A 93 (1996) 14128-14133
25. Engber T.M., Dennis S.A., Jones B.E., Miller M.S., and Contreras P.C. Brain regional substrates for the actions of the novel wake-promoting agent modafinil in the rat: comparison with amphetamine. Neuroscience 87 (1998) 905-911